Get insights on Biogen’s Leqembi sales outlook, clinical value, risks, and what new drug approvals may mean for investors.

A new study published in Addiction has identified genetic factors that influence both a person’s risk of developing an addiction and their educational attainment. Researchers found that some genetic ...

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

Bristol Myers Squibb BMY recently announced that it will continue the phase III ADEPT-2 study on Cobenfy in psychosis ...

Days after Johnson & Johnson’s posdinemab failed to slow clinical decline in patients with Alzheimer’s disease, Eisai Chief ...

An autoinjector to administer Leqembi to patients with early-stage Alzheimer’s disease had high degrees of satisfaction for utility, feasibility and convenience for use at home, according to a poster.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on time saved with continued treatment with lecanemab (Leqembi®) at the 18th Clinical Trials in Alzheimer's ...

Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

More than nine in 10 patients treated with Roche’s next-generation Alzheimer’s disease antibody trontinemab tested negative for amyloid plaques in a mid-stage study, marking a return to the ...

Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle ...